Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Plasma cell 1Lymphoid 1Genitourinary 1CNS 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 65Cisplatin 42Cetuximab 36Radiotherapy 28Nivolumab 26Paclitaxel 22Carboplatin 22Docetaxel 20durvalumab 14Radiotherapy, Intensity-Modulated 12Fluorouracil 12Cyclophosphamide 11tremelimumab 9Gemcitabine 9Ipilimumab 8fludarabine 7avelumab 7Erlotinib Hydrochloride 7toripalimab 6epacadostat 6cemiplimab 6Radiosurgery 6Interleukin-2 6Capecitabine 6Bevacizumab 6spartalizumab 5Celecoxib 5zalutumumab 4tislelizumab 4fludarabine phosphate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × MLN 8237 × Head & Neck × Clear all
NCT04555837 2025-05-20

Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
24 enrolled 13 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01045421 2016-08-15

Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

Millennium Pharmaceuticals, Inc.

Phase 1/2 Completed
273 enrolled 28 charts
BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡